Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid Effects on FXR and Microbiota in Obesity
NCT02532335Phase 1Unknown
- Sponsor
- Sahlgrenska University Hospital
- Start
- Aug 2015
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of obeticholic acid in obesity (4 arms), sponsored by Sahlgrenska University Hospital. Primary endpoints: Activation of FXR-dependent genes in small intestine at 3 weeks, Small intestinal permeability at 3 weeks and 1 more. Status: unknown.
02
Drugs
obeticholic acid
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02532335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532335.